Ontology highlight
ABSTRACT: Background and aims
Therapies for chronic hepatitis B virus (HBV) infection are urgently needed because of viral integration, persistence of viral antigen expression, inadequate HBV-specific immune responses, and treatment regimens that require lifelong adherence to suppress the virus. Immune mobilizing monoclonal T Cell receptors against virus (ImmTAV) molecules represent a therapeutic strategy combining an affinity-enhanced T Cell receptor with an anti-CD3 T Cell-activating moiety. This bispecific fusion protein redirects T cells to specifically lyse infected cells expressing the target virus-derived peptides presented by human leukocyte antigen (HLA).Approach and results
ImmTAV molecules specific for HLA-A*02:01-restricted epitopes from HBV envelope, polymerase, and core
SUBMITTER: Fergusson JR
PROVIDER: S-EPMC7702151 | biostudies-literature | 2020 Nov
REPOSITORIES: biostudies-literature